✕
Login
Register
Back to News
BioCryst Pharma Affirms FY2026 Sales Guidance of $635.000M-$660.000M vs $650.217M Est
Benzinga Newsdesk
www.benzinga.com
Negative 65.5%
Neg 65.5%
Neu 0%
Pos 0%
Comments
No comments yet. Be the first!
Join the discussion
Login to comment
Login to comment